← Back to Screener
Nuwellis, Inc. Common Stock (NUWE)
Price$1.19
Favorite Metrics
Price vs S&P 500 (26W)-71.58%
Price vs S&P 500 (4W)11.97%
Market Capitalization$2.83M
All Metrics
Book Value / Share (Quarterly)$2.87
P/TBV (Annual)0.83x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)3.34%
Cash Flow / Share (Quarterly)$-6.89
Price vs S&P 500 (YTD)-32.24%
Gross Margin (TTM)59.07%
Net Profit Margin (TTM)-202.83%
EPS (TTM)$-107.67
10-Day Avg Trading Volume0.04M
EPS Excl Extra (TTM)$-107.67
Revenue Growth (5Y)9.67%
EPS (Annual)$-353.32
ROI (Annual)-170.98%
Gross Margin (Annual)64.94%
Net Profit Margin (5Y Avg)-197.12%
Cash / Share (Quarterly)$2.27
Revenue Growth QoQ (YoY)-6.34%
ROA (Last FY)-113.19%
Revenue Growth TTM (YoY)-8.93%
EBITD / Share (TTM)$-18.78
ROE (5Y Avg)-218.06%
Operating Margin (TTM)-124.27%
Cash Flow / Share (Annual)$-92.67
P/B Ratio0.72x
P/B Ratio (Quarterly)1.17x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)-0.03x
Net Interest Coverage (TTM)-0.99x
ROA (TTM)-194.60%
EPS Growth QoQ (YoY)-99.24%
EPS Incl Extra (Annual)$-353.32
Current Ratio (Annual)3.46x
Quick Ratio (Quarterly)1.42x
3-Month Avg Trading Volume1.48M
52-Week Price Return-96.76%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$4.20
P/S Ratio (Annual)0.32x
Asset Turnover (Annual)0.89x
52-Week High$45.42
Operating Margin (5Y Avg)-198.17%
EPS Excl Extra (Annual)$-353.32
CapEx CAGR (5Y)-34.30%
Tangible BV CAGR (5Y)-5.32%
26-Week Price Return-67.59%
Quick Ratio (Annual)2.79x
13-Week Price Return-39.36%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.04x
Enterprise Value$-0.264
Revenue / Share Growth (5Y)-80.58%
Asset Turnover (TTM)0.96x
Book Value / Share Growth (5Y)-83.36%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.65x
Pretax Margin (Annual)-127.69%
Cash / Share (Annual)$48.92
3-Month Return Std Dev194.59%
Gross Margin (5Y Avg)57.63%
Net Income / Employee (TTM)$-0
ROE (Last FY)-170.98%
Net Interest Coverage (Annual)-0.19x
EPS Basic Excl Extra (Annual)$-353.32
Receivables Turnover (TTM)6.71x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-107.67
Receivables Turnover (Annual)4.75x
ROI (TTM)-85.85%
P/S Ratio (TTM)0.35x
Pretax Margin (5Y Avg)-197.04%
Revenue / Share (Annual)$276.58
Tangible BV / Share (Annual)$23.04
Price vs S&P 500 (52W)-126.59%
Year-to-Date Return-29.60%
5-Day Price Return13.43%
EPS Normalized (Annual)$-353.32
ROA (5Y Avg)-104.47%
Net Profit Margin (Annual)-127.75%
Month-to-Date Return16.67%
Cash Flow / Share (TTM)$-13.85
EBITD / Share (Annual)$-165.92
Operating Margin (Annual)-115.42%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-217.88%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-107.67
P/TBV (Quarterly)0.83x
P/B Ratio (Annual)0.74x
Inventory Turnover (TTM)1.65x
Pretax Margin (TTM)-202.75%
Book Value / Share (Annual)$62.70
Price vs S&P 500 (13W)-40.04%
Beta0.33x
Revenue / Share (TTM)$9.77
ROE (TTM)-85.85%
52-Week Low$0.96
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
2.17
2.17
2.17
2.17
Industry Peers — Electromedical Equipment(29)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
NUWENuwellis, Inc. Common Stock | 0.35x | 9.67% | 59.07% | -124.27% | $1.19 |
MDTMedtronic plc | 3.13x | 3.01% | 65.16% | 17.00% | $85.65 |
MASIMasimo Corporation | 6.12x | 5.95% | 61.90% | 20.30% | $178.29 |
TMDXTransMedics Group, Inc. Common Stock | 6.58x | 88.21% | 59.92% | 17.93% | $109.12 |
LIVNLivaNova PLC Ordinary Shares | 2.56x | 8.24% | 68.04% | 14.09% | $65.01 |
ITGRInteger Holdings Corporation | 1.63x | 11.55% | 27.39% | 11.90% | $88.37 |
AXGNAxogen, Inc. Common Stock | 7.92x | 14.93% | 74.31% | -3.49% | $37.37 |
CNMDCONMED Corporation | 0.88x | 9.77% | 54.59% | 7.46% | $37.91 |
BLFSBioLife Solutions Inc. | 10.59x | 14.87% | 64.56% | -17.26% | $20.85 |
INMDInMode Ltd. Ordinary Shares | 2.45x | 12.45% | 78.54% | 23.05% | $14.33 |
CBLLCeriBell, Inc. Common Stock | 8.68x | — | 87.89% | -65.57% | $20.74 |
About
Nuwellis Inc manufactures ultrafiltration devices for treating fluid overload in patients unresponsive to conventional medical management. The company's primary products, the Aquadex FlexFlow and Aquadex SmartFlow systems, remove excess fluid in conditions such as congestive heart failure. Nuwellis operates a single business segment focused on fluid overload treatment.